These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28842696)

  • 1. Adhesion to stromal cells mediates imatinib resistance in chronic myeloid leukemia through ERK and BMP signaling pathways.
    Kumar A; Bhattacharyya J; Jaganathan BG
    Sci Rep; 2017 Aug; 7(1):9535. PubMed ID: 28842696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes microenvironment-mediated imatinib resistance in chronic myeloid leukemia.
    Liu P; Ma D; Yu Z; Zhe N; Ren M; Wang P; Yu M; Huang J; Fang Q; Wang J
    Biomed Pharmacother; 2017 Jul; 91():21-30. PubMed ID: 28445830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia.
    Chorzalska A; Ahsan N; Rao RSP; Roder K; Yu X; Morgan J; Tepper A; Hines S; Zhang P; Treaba DO; Zhao TC; Olszewski AJ; Reagan JL; Liang O; Gruppuso PA; Dubielecka PM
    Mol Oncol; 2018 May; 12(5):630-647. PubMed ID: 29485707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oroxylin A reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12/CXCR7 axis in bone marrow microenvironment.
    Li W; Ding Q; Ding Y; Lu L; Wang X; Zhang Y; Zhang X; Guo Q; Zhao L
    Mol Carcinog; 2017 Mar; 56(3):863-876. PubMed ID: 27533597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EphB4-VAV1 signaling pathway is associated with imatinib resistance in chronic myeloid leukemia cells.
    Zhang JF; Xu N; Du QF; Li R; Liu XL
    Blood Cells Mol Dis; 2016 Jul; 59():58-62. PubMed ID: 27282569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. microRNA-199a/b-5p enhance imatinib efficacy via repressing WNT2 signaling-mediated protective autophagy in imatinib-resistant chronic myeloid leukemia cells.
    Chen PH; Liu AJ; Ho KH; Chiu YT; Anne Lin ZH; Lee YT; Shih CM; Chen KC
    Chem Biol Interact; 2018 Aug; 291():144-151. PubMed ID: 29890129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of crosstalk between Bcr-Abl and PKC signaling by PEITC, augments imatinib sensitivity in chronic myelogenous leukemia cells.
    Roy M; Sarkar R; Mukherjee A; Mukherjee S
    Chem Biol Interact; 2015 Dec; 242():195-201. PubMed ID: 26456889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms.
    Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Carter BZ; Wang X; Shi X; Liu J
    J Hematol Oncol; 2016 Nov; 9(1):129. PubMed ID: 27884201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinesin spindle protein inhibitor SB743921 induces mitotic arrest and apoptosis and overcomes imatinib resistance of chronic myeloid leukemia cells.
    Yin Y; Sun H; Xu J; Xiao F; Wang H; Yang Y; Ren H; Wu CT; Gao C; Wang L
    Leuk Lymphoma; 2015 Jun; 56(6):1813-20. PubMed ID: 25146433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BM microenvironmental protection of CML cells from imatinib through Stat5/NF-κB signaling and reversal by Wogonin.
    Xu X; Zhang X; Liu Y; Yang L; Huang S; Lu L; Wang S; Guo Q; Zhao L
    Oncotarget; 2016 Apr; 7(17):24436-54. PubMed ID: 27027438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
    Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway.
    Li X; Miao H; Zhang Y; Li W; Li Z; Zhou Y; Zhao L; Guo Q
    Arch Toxicol; 2015 Jan; 89(1):121-36. PubMed ID: 24671465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
    Lin TY; Chen KC; Liu HJ; Liu AJ; Wang KL; Shih CM
    PLoS One; 2016; 11(5):e0156260. PubMed ID: 27228340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC.
    Fenouille N; Puissant A; Dufies M; Robert G; Jacquel A; Ohanna M; Deckert M; Pasquet JM; Mahon FX; Cassuto JP; Raynaud S; Tartare-Deckert S; Auberger P
    Cancer Res; 2010 Dec; 70(23):9659-70. PubMed ID: 21098700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
    Tsubaki M
    Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-153-3p enhances the sensitivity of chronic myeloid leukemia cells to imatinib by inhibiting B-cell lymphoma-2-mediated autophagy.
    Li YL; Tang JM; Chen XY; Luo B; Liang GH; Qu Q; Lu ZY
    Hum Cell; 2020 Jul; 33(3):610-618. PubMed ID: 32342278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-methylumbelliferone and imatinib combination enhances senescence induction in chronic myeloid leukemia cell lines.
    Lompardía SL; Díaz M; Papademetrio DL; Pibuel M; Álvarez É; Hajos SE
    Invest New Drugs; 2017 Feb; 35(1):1-10. PubMed ID: 27718039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High IL-7 levels in the bone marrow microenvironment mediate imatinib resistance and predict disease progression in chronic myeloid leukemia.
    Zhang X; Tu H; Yang Y; Wan Q; Fang L; Wu Q; Li J
    Int J Hematol; 2016 Sep; 104(3):358-67. PubMed ID: 27272942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro.
    Liu MY; Wang WZ; Liao FF; Wu QQ; Lin XH; Chen YH; Cheng L; Jin XB; Zhu JY
    Cell Biol Int; 2017 Jan; 41(1):16-23. PubMed ID: 27677634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of Smad4 expression confers chemoresistance against imatinib mesylate to chronic myeloid leukemia K562 cells.
    Zhang J; Zhang M; Liang Y; Liu M; Huang Z
    Hematology; 2022 Dec; 27(1):43-52. PubMed ID: 34957936
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.